This report analyzes the worldwide markets for Analgesics in Millions of US$. The major product segments analyzed are Internal Analgesics, (Aspirin, Acetaminophen, Ibuprofen, and Others (includes combination drugs)) and External Analgesics. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2001 through 2015. A ten-year historic analysis is also provided for these markets with annual market analytics. The report profiles 139 companies including many key and niche players worldwide such as Bayer Consumer Care, Bristol-Myers Squibb Co., Johnson & Johnson, McNeil Consumer Healthcare, Novartis International AG, Pfizer, Inc., Reckitt Benckiser Group Plc, W. F. Young, Inc., Wyeth, and Wyeth Consumer Healthcare. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANALGESICS									MCP-5064
A GLOBAL STRATEGIC BUSINESS REPORT


                                           CONTENTS



  I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

      Study Reliability and Reporting Limitations                       I-1
      Disclaimers                                                       I-2
      Data Interpretation & Reporting Level                             I-2
       Quantitative Techniques & Analytics                              I-3
      Product Definitions and Scope of Study                            I-3
       1. Internal Analgesics                                           I-3
         Aspirin                                                        I-3
         Acetaminophen                                                  I-3
         Ibuprofen                                                      I-4
         Others                                                         I-4
       2. External Analgesics                                           I-4


 II. EXECUTIVE SUMMARY

  1. Global Analgesics Market Overview                                  II-1
      Pain Therapeutic Market                                           II-1
      Analgesics Market - Offering Immense Potential                    II-1
      Internal Analgesics - Riding on a Crest                           II-1
       Liquid Analgesics Register Rapid Growth                          II-2
       Neuropathic Pain- Unexplored                                     II-2
       Ibuprofen Scoring High                                           II-2
      External Analgesics - In a slump                                  II-2
       Boom in Demand for Topical Analgesic Patches                     II-3

  2. Product Overview                                                   II-4
      A Brief History                                                   II-4
      Analgesics                                                        II-4
       Definition                                                       II-4
      Types of Pain                                                     II-4
      Acute Pain                                                        II-4
      Chronic Pain                                                      II-5
      Drugs Combating Pain                                              II-5
       Local Anesthetics                                                II-5
       Narcotic Opioids                                                 II-5
       Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                    II-6
        Types of NSAIDS                                                 II-6
        Common NSAIDs                                                   II-7
        Clinical Use...                                                 II-7
        Side Effects...                                                 II-8
      Aspirin                                                           II-8
       The Wonder Drug...                                               II-8
       PolyAspirin: The Safer and More Potent Polymer Variant of
        Aspirin                                                         II-9
       Mode of Action                                                   II-9
       Contraindications                                                II-9
      Acetaminophen                                                     II-9
       Acetaminophen Protects Heart Muscle                              II-10
       Acetaminophen Reduces Incidence of Ovarian Cancer                II-10
      Ibuprofen, Ketoprofen and Naproxen                                II-10
      Combination Analgesics                                            II-10
       Table 1: Opioid Analgesics Market: Percentage Share of Opioid
       / Acetaminophen Combination Products in the Opioid Script
       Volume (includes corresponding Graph/Chart)                      II-11
      OTC Analgesics: An Overview                                       II-11

  3. Industry Dynamics                                                  II-12
      Escalating R&D Costs: A Boon or Bane?                             II-12
       Timeline of the Drug Approval Process                            II-12
      Cox II Crisis Tarnishes Industry Growth                           II-12
      Novel Therapies to Propel Opioid and Non-Opioid Therapies         II-13
      Rx-to-OTC Switch                                                  II-13
      Why Consumers Prefer OTC Drugs?                                   II-13
      Development of Analgesic Tripeptides                              II-13

  4. Recent Clinical Trials                                             II-14
      PLx Initiates Clinical Trial For Aspirin-PC                       II-14
      Neurodiscovery Receives Approval for NSL-101 Phase II Clinical
       Trials                                                           II-14

  5. Product Innovations/Introductions                                  II-15
      ProEthic Pharmaceuticals Releases Ibudone for Acute Pain
       Management                                                       II-15
      Dr. Reddy's Laboratories Introduces Supanac for Acute Pain
       Management                                                       II-15
      Mallinckrodt Introduces Magnacet Tablets for Pain Management     II-15
      Wockhardt to Launch New Painkiller                                II-15
      Paladin Labs and Labopharm Introduce Tridural                    II-15
      Shionogi & Co Introduces OxiNorm Powder 0.5%                      II-15
      McNeil Brings Chewable TYLENOL(R) GoTabs Tablets                    II-16
      Barr Unveils Generic Version of ACTIQ(R)                            II-16
      Novartis Launches Voltarol Pain-Eze Emulgel .                     II-16
      TheraQuest Launches TQ-1017                                       II-16
      Mentholatum Company Introduces WellPatch Deep Heat Patch          II-16
      SSP and Mepha Launch Olfen Patch in Switzerland                   II-17
      W.F. Young Expands Absorbine Jr(R)                                  II-17
      Pfizer Unveils Neurontin                                          II-17
      Ligand Pharmaceuticals Introduces Avinza in the US                II-17
      AlphaRx Introduces Flexogan                                       II-17
      Essere Introduces Roll-On Analgesic                               II-17
      Novartis Introduces Topical Analgesic and Cough Suppressant in
       Sticks                                                           II-17
      SSL International Introduces Easy-To-Swallow Version of Paramol   II-18
      Janssen Launches Duragesic, a Narcotic Analgesic                  II-18
      Abbott Laboratories Launches Narcotic Analgesic                   II-18
      Ortho-McNeil Launches Flexeril                                    II-18
      Elkins-Sinn Launches Opioid Analgesic                             II-18
      FH Faulding Launches Narcotic Analgesic, Kadian                   II-18
      ICN Pharmaceuticals Launches Opioid Aanalgesic, Levo Dromoran     II-18
      Amarin Launches Motofen, a Narcotic Analgesic and Anti-
       Cholinergic                                                      II-18
      Purdue Pharma Launches MS Contin, a Narcotic Analgesic            II-19
      Able Laboratories Unveils New Versions of Acetaminophen and
       Hydrocodone Bitartrate                                           II-19
      Whitehall Launches Anadin Analgesic Tablets in South Africa       II-19
      Leiner Launches Ibuprofen Softgel Capsules                        II-19
      Crookes Healthcare Launches Ibuprofen Singles for Children        II-19
      SSL International Launches Cuprofen Ibuprofen for Children        II-19
      Lloydspharmacy Launches Ibuprofen Suspension for Children         II-19

  6. Recent Industry Activity                                           II-20
      Bayer to Acquire Sagmel's OTC Business                            II-20
      E5 Pharma Receives Approval from FDA                              II-20
      Pharmaceutical Associates Receives Approval from FDA              II-20
      Concord Receives New Drug Approvals                               II-20
      Hisamitsu Receives Approval for SALONPAsÒ                         II-20
      Johnson & Johnson Submits NDA to FDA                              II-20
      Nycomed and Paladin Inks Joint-Promotion Agreement for Tridural   II-20
      Akela Extends Agreement with Janssen                              II-21
      Daiichi and Lead Chemical Receives Approval for LoxoninÒ Tape     II-21
      Tokio Marine Capital to Acquire Showa Yakuhin Kako                II-21
      Corgenix Collaborates with Randox Laboratories                    II-21
      Corgenix Receives EPO Approval for Aspirin Resistance Method      II-21
      IOL to Expand Production Capacity                                 II-22
      American Oriental Bioengineering Partners with China Aoxing       II-22
      Abraxis Takes Over Shimoda and its Subsidiary Co.                 II-22
      Ranbaxy Receives Approval from FDA                                II-22
      Wockhardt Receives FDA Approval for DPN + APAP                    II-22
      Alpharma to Market Flector(R) Patch in the US                       II-22
      Auriga and Mikart Inks Agreement to Market Codein                 II-22
      Watson Receives FDA Approval for Oxycodone Hydrochloride and
       Ibuprofen                                                        II-23
      Labopharm's Tramadol Receives Approval in Canada                  II-23
      Lion Acquires BUFFERIN(R) Trademark Rights                          II-23
      Grunenthal's Extends Licensing Agreement with Ortho-McNeil        II-23
      China Aoxing Pockets LRT                                          II-23
      Anesiva Inks Joint Venture Agreement Wanbang                      II-23
      Beijing Med-Pharm Inks Agreement with Lotus Healthcare            II-24
      LAB International Inks Licensing Agreement with Janssen
       Pharmaceutica                                                    II-24
      Three Sixty Pockets Rockford-Montgomery Labs                      II-24
      Antares Enters into License and Development Agreement for
       Opioid Analgesic                                                 II-24
      Abraxis BioScience Acquires AstraZeneca's Analgesic Brand
       Portfolio                                                        II-24
      IntelliPharmaCeutics Inks Agreement with Larasan                  II-24
      Ranbaxy and Ethypharm Ink In-licensing Agreement                  II-25
      Elite Collaborates with TPN to Co-develop Analgesic Drug          II-25
      Novartis Acquires Hexal Company and Major Stake in Eon Labs .     II-25
      NovaDel Pharma Receives Patent for Buccal Sprays Technology       II-25
      Auxilium Pharmaceuticals Enters into a Licensing Agreement
       with PharmaForm                                                  II-25
      EC Sanctions Sale of Elan's Prialt                                II-26
      EpiCept Corp. Merges with Maxim Pharmaceuticals, Inc              II-26
      Reckitt Benckiser plc Acquires Boots Healthcare International     II-26
      Bayer Acquires Non-prescription Drug Business of Roche            II-26
      Bextra (Valdecoxib) Receives Green Signal from Health Canada      II-27
      Rhodia Announces Closure of Acetaminophen Plant in Louisiana      II-27
      NicOx Re-Gains Rights to CINOD from AstraZeneca                   II-27

  7. Focus on Select Key Players                                        II-28
      Bayer Consumer Care (USA)                                         II-28
      Bristol-Myers Squibb Company (USA)                                II-28
      Johnson & Johnson (USA)                                           II-28
       McNeil Consumer Healthcare (Canada)                              II-28
      Novartis International AG (Switzerland)                           II-29
      Pfizer Inc. (USA)                                                 II-29
      Reckitt Benckiser Group Plc (UK)                                  II-29
      W. F. Young Inc (USA)                                             II-29
      Wyeth (USA)                                                       II-30
       Wyeth Consumer Healthcare                                        II-30

  8. Global Market Perspective                                          II-31
      Table 2: World Recent Past, Current & Future Analysis for
      Analgesics by Geographic Region/Country - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), Latin America and Rest
      of World Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2001 through 2010 (includes
      corresponding Graph/Chart)                                        II-31

      Table 3: World Long-term Projections for Analgesics by
      Geographic Region/Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-32

      Table 4: World Historic Review for Analgesics by Geographic
      Region/Country - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), Latin America and Rest of World Markets
      Independently Analyzed with Annual Sales Figures in US$
      Million for Years 1991 through 2000 (includes corresponding
      Graph/Chart)                                                      II-33

      Table 5: World 15-Year Perspective for Analgesics by
      Geographic Region/Country - Percentage Breakdown of Dollar
      Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
      Japan), Latin America and Rest of World Markets for Years
      1998, 2008 & 2012 (includes corresponding Graph/Chart)            II-34

      Table 6: World Recent Past, Current & Future Analysis for
      Internal Analgesics by Geographic Region/ Country - US,
      Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
      America and Rest of World Markets Independently Analyzed with
      Annual Sales Figures in US$ Million for Years 2001 through
      2010 (includes corresponding Graph/Chart)                         II-35

      Table 7: World Long-term Projections for Internal Analgesics
      by Geographic Region / Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-36

      Table 8: World Historic Review for Internal Analgesics by
      Geographic Region/Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 1991 through 2000 (includes
      corresponding Graph/Chart)                                        II-37

      Table 9: World 15-Year Perspective for Internal Analgesics by
      Geographic Region/Country - Percentage Breakdown of Dollar
      Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
      Japan), Latin America and Rest of World Markets for Years
      1998, 2008 & 2012 (includes corresponding Graph/Chart)            II-38

      Table 10: World Recent Past, Current & Future Analysis for
      Internal Analgesics by Product Segment - Aspirin,
      Acetaminophen, Ibuprofen, and Others Markets Independently
      Analyzed with Annual Sales Figures in US$ Million for Years
      2001 through 2010 (includes corresponding Graph/Chart)            II-39

      Table 11: World Long-term Projections for Internal Analgesics
      by Product Segment - Aspirin, Acetaminophen, Ibuprofen, and
      Others Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-39

      Table 12: World Historic Review for Internal Analgesics by
      Product Segment - Aspirin, Acetaminophen, Ibuprofen, and
      Others Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 1991 through 2000 (includes
      corresponding Graph/Chart)                                        II-40

      Table 13: World 15-Year Perspective for Internal Analgesics by
      Product Segment - Percentage Breakdown of Dollar Sales for
      Aspirin, Acetaminophen, Ibuprofen, and Others Markets for
      Years 1998, 2008 & 2012 (includes corresponding Graph/Chart)      II-40

      Table 14: World Recent Past, Current & Future Analysis for
      Aspirin by Geographic Region/Country - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), Latin America and Rest
      of World Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2001 through 2010 (includes
      corresponding Graph/Chart)                                        II-41

      Table 15: World Long-term Projections for Aspirin by
      Geographic Region/Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-42

      Table 16: World Historic Review for Aspirin by Geographic
      Region/Country - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), Latin America and Rest of World Markets
      Independently Analyzed with Annual Sales Figures in US$
      Million for Years 1991 through 2000 (includes corresponding
      Graph/Chart)                                                      II-43

      Table 17: World 15-Year Perspective for Aspirin by Geographic
      Region/Country - Percentage Breakdown of Dollar Sales for US,
      Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
      America and Rest of World Markets for Years 1998, 2008 & 2012
      (includes corresponding Graph/Chart)                              II-44

      Table 18: World Recent Past, Current & Future Analysis for
      Acetaminophen by Geographic Region/ Country - US, Canada,
      Japan, Europe, Asia-Pacific (excluding Japan), Latin America
      and Rest of World Markets Independently Analyzed with Annual
      Sales Figures in US$ Million for Years 2001 through 2010
      (includes corresponding Graph/Chart)                              II-45

      Table 19: World Long-term Projections for Acetaminophen by
      Geographic Region/Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-46

      Table 20: World Historic Review for Acetaminophen by
      Geographic Region/Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 1991 through 2000 (includes
      corresponding Graph/Chart)                                        II-47

      Table 21: World 15-Year Perspective for Acetaminophen by
      Geographic Region/Country - Percentage Breakdown of Dollar
      Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
      Japan), Latin America and Rest of World Markets for Years
      1998, 2008 & 2012 (includes corresponding Graph/Chart)            II-48

      Table 22: World Recent Past, Current & Future Analysis for
      Ibuprofen by Geographic Region/Country - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), Latin America and Rest
      of World Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2001 through 2010 (includes
      corresponding Graph/Chart)                                        II-49

      Table 23: World Long-term Projections for Ibuprofen by
      Geographic Region/Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-50

      Table 24: World Historic Review for Ibuprofen by Geographic
      Region/Country - US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), Latin America and Rest of World Markets
      Independently Analyzed with Annual Sales Figures in US$
      Million for Years 1991 through 2000 (includes corresponding
      Graph/Chart)                                                      II-51

      Table 25: World 15-Year Perspective for Ibuprofen by
      Geographic Region/Country - Percentage Breakdown of Dollar
      Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
      Japan), Latin America and Rest of World Markets for Years
      1998, 2008 & 2012 (includes corresponding Graph/Chart)            II-52

      Table 26: World Recent Past, Current & Future Analysis for
      *Other Internal Analgesics by Geographic Region/Country - US,
      Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
      America and Rest of World Markets Independently Analyzed with
      Annual Sales Figures in US$ Million for Years 2001 through
      2010 (includes corresponding Graph/Chart)                         II-53

      Table 27: World Long-term Projections for *Other Internal
      Analgesics by Geographic Region/Country - US, Canada, Japan,
      Europe, Asia-Pacific (excluding Japan), Latin America and Rest
      of World Markets Independently Analyzed with Annual Sales
      Figures in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-54

      Table 28: World Historic Review for *Other Internal Analgesics
      by Geographic Region / Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 1991 through 2000 (includes
      corresponding Graph/Chart)                                        II-55

      Table 29: World 15-Year Perspective for *Other Internal
      Analgesics by Geographic Region/Country - Percentage Breakdown
      of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
      (excluding Japan), Latin America and Rest of World Markets for
      Years 1998, 2008 & 2012 (includes corresponding Graph/Chart)      II-56

      Table 30: World Recent Past, Current & Future Analysis for
      External Analgesics by Geographic Region/ Country - US,
      Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin
      America and Rest of World Markets Independently Analyzed with
      Annual Sales Figures in US$ Million for Years 2001 2010
      (includes corresponding Graph/Chart)                              II-57

      Table 31: World Long-term Projections for External Analgesics
      by Geographic Region / Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 2011 through 2015 (includes
      corresponding Graph/Chart)                                        II-58

      Table 32: World Historic Review for External Analgesics by
      Geographic Region/Country - US, Canada, Japan, Europe,
      Asia-Pacific (excluding Japan), Latin America and Rest of
      World Markets Independently Analyzed with Annual Sales Figures
      in US$ Million for Years 1991 2000 (includes corresponding
      Graph/Chart)                                                      II-59

      Table 33: World 15-Year Perspective for External Analgesics by
      Geographic Region /Country - Percentage Breakdown of Dollar
      Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding
      Japan), Latin America and Rest of World Markets for Years
      1998, 2008 & 2012 (includes corresponding Graph/Chart)            II-60


III-A. MARKET

  1. The United States                                                  III-1
      A.Market Analysis                                                 III-1
        Current and Future Analysis                                     III-1
        Pain Statistics in the US                                       III-1
        Industry Overview                                               III-1
         Internal Analgesics                                            III-2
          Cox-2 Drugs in for Some Trouble                               III-2
          Switch to OTC Drugs                                           III-2
           Table 34: US Internal Tablet Analgesics Market (2007):
           Percentage Share Breakdown of Leading Ten Brands by
           Revenues (includes corresponding Graph/Chart)                III-2

           Table 35: US Internal Liquid Analgesics Market (2007):
           Percentage Share Breakdown of Leading Ten Brands by
           Revenues (includes corresponding Graph/Chart)                III-3

           Table 36: Internal Analgesics Market in the U.S. By
           Retail Channel (2008E): Percentage Share by Value Sales
           for Discount Stores, Food / Drug Combination Stores,
           Chain Drug Stores, Supermarkets, and Independent Drug
           Stores (includes corresponding Graph/Chart)                  III-3
          Promotional Strategies for the Internal Analgesics            III-3
           Table 37: Market for Internal Liquid Analgesics in the
           U.S. by Retail Channel (2008E): Percentage Share by Value
           Sales for Supermarkets, Drug Stores, and Discounters
           (includes corresponding Graph/Chart)                         III-3
          Pediatric Analgesics: The New Kid on the Block                III-4
          External Analgesics                                           III-4
          Stretching Boundaries                                         III-4
           Table 38: US External Analgesics Market (2007):
           Percentage Share Breakdown of Leading Ten Brands by
           Revenues (includes corresponding Graph/Chart)                III-4

           Table 39: External Analgesics Market in the U.S. By
           Retail Channel (2008E): Percentage Share by Value Sales
           for Chain drug stores, Discount stores, Food/drug
           combination stores, Independent drug stores, and
           Supermarkets (includes corresponding Graph/Chart)            III-4
          Rubs, Patches: Driving the External Analgesics Market         III-4
          Patch Relief Gaining Momentum                                 III-5
        Product Innovations/Introductions                               III-5
        Strategic Corporate Developments                                III-6
        Major Players                                                   III-9
      B.Market Analytics                                                III-11
        Table 40: US Recent Past, Current & Future Analysis for
        Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2001 through 2010 (includes
        corresponding Graph/Chart)                                      III-11

        Table 41: US Long-term Projections for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2011 through 2015 (includes corresponding
        Graph/Chart)                                                    III-12

        Table 42: US Historic Review for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 1991 through 2000 (includes corresponding
        Graph/Chart)                                                    III-12

        Table 43: US 15-Year Perspective for Analgesics by Product
        Segment - Percentage Breakdown of Dollar Sales for Internal
        Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
        and External Analgesics Markets for 1998, 2008 & 2012
        (includes corresponding Graph/Chart)                            III-13

  2. Canada                                                             III-14
      A.Market Analysis                                                 III-14
        Current and Future Analysis                                     III-14
        Key Players                                                     III-14
         McNeil Consumer Healthcare                                     III-14
        Product Launches                                                III-14
        Strategic Corporate Developments                                III-14
      B.Market Analytics                                                III-16
        Table 44: Canadian Recent Past, Current & Future Analysis
        for Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2001 through 2010 (includes
        corresponding Graph/Chart)                                      III-16

        Table 45: Canadian Long-term Projections for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-17

        Table 46: Canadian Historic Review for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 1991 through 2000 (includes corresponding
        Graph/Chart)                                                    III-17

        Table 47: Canadian 15-Year Perspective for Analgesics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
        Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-18

  3. Japan                                                              III-19
      A.Market Analysis                                                 III-19
        Current and Future Analysis                                     III-19
        Competitive Scenario                                            III-19
         Table 48: OTC Analgesics Market in Japan (2005): Market
         Share of Leading Players by Value - Lion, Arax, Taisho
         Pharmaceutical, SS Pharmaceutical, Shionogi, and Others
         (includes corresponding Graph/Chart)                           III-19
        Strategic Corporate Developments                                III-19
      B.Market Analytics                                                III-21
        Table 49: Japanese Recent Past, Current & Future Analysis
        for Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2001 through 2010 (includes
        corresponding Graph/Chart)                                      III-21

        Table 50: Japanese Long-term Projections for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-22

        Table 51: Japanese Historic Review for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 1991 through 2000 (includes corresponding
        Graph/Chart)                                                    III-22

        Table 52: Japanese 15-Year Perspective for Analgesics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
        Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-23

  4. Europe                                                             III-24
      A.Market Analysis                                                 III-24
        Current and Future Analysis                                     III-24
         By Product Group/Segment                                       III-24
        European Pain Management Market                                 III-24
        Generics Restrain Revenue Growth                                III-24
         Table 53: Popular Brands of Pain & Inflammation Medication
         in Europe (2004): Percentage Share of Aspirin, Voltaren,
         Ibuprofen, Nurofen, Vioxx, Celebre, Tylenol, Aulin, Anadin,
         and Paracetamol (includes corresponding Graph/Chart)           III-25
      B.Market Analytics                                                III-26
        Table 54: European Recent Past, Current & Future Analysis
        for Analgesics by Geographic Region/Country - France,
        Germany, UK, Italy, Spain, Russia and Rest of Europe Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2001 through 2010 (includes corresponding
        Graph/Chart)                                                    III-26

        Table 55: European Long-term Projections for Analgesics by
        Geographic Region/Country - France, Germany, UK, Italy,
        Spain, Russia and Rest of Europe Markets Independently
        Analyzed with Annual Sales Figures in US$ Million for Years
        2011 through 2015 (includes corresponding Graph/Chart)          III-26

        Table 56: European Recent Past, Current & Future Analysis
        for Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2001 through 2010 (includes
        corresponding Graph/Chart)                                      III-27

        Table 57: European Long-term Projections for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-27

        Table 58: European Historic Review for Analgesics by
        Geographic Region/Country - France, Germany, UK, Italy,
        Spain, Russia and Rest of Europe Markets Independently
        Analyzed with Annual Sales Figures in US$ Million for Years
        1991 through 2000 (includes corresponding Graph/Chart)          III-28

        Table 59: European Historic Review for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 1991 through 2000 (includes corresponding
        Graph/Chart)                                                    III-28

        Table 60: European 15-Year Perspective for Analgesics by
        Geographic Region/Country - Percentage Breakdown of Dollar
        Sales for France, Germany, UK, Italy, Spain, Russia and Rest
        of Europe Markets for Years 1998, 2008 & 2012 (includes
        corresponding Graph/Chart)                                      III-29

        Table 61: European 15-Year Perspective for Analgesics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
        Others) and External Analgesics Markets for Years 1998, 2008
        & 2012 (includes corresponding Graph/Chart)                     III-30

  4a. France                                                            III-31
      A.Market Analysis                                                 III-31
        Current and Future Analysis                                     III-31
        Competitive Scenario                                            III-31
         Table 62: Analgesics Market in France (2005): Market Share
         of Leading Players by Value - Bristol-Myers Squibb,
         Therapix, Roche, Bayer Group, Wyeth Consumer Healthcare,
         and Others) (includes corresponding Graph/Chart)               III-31
        Key Player                                                      III-31
         Sanofi Aventis                                                 III-31
      B.Market Analytics                                                III-32
        Table 63: French Recent Past, Current & Future Analysis for
        Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2001 through 2010 (includes
        corresponding Graph/Chart)                                      III-32

        Table 64: French Long-term Projections for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 2011 through 2015(includes
        corresponding Graph/Chart)                                      III-33

        Table 65: French Historic Review for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 1991 through 2000 (includes corresponding
        Graph/Chart)                                                    III-33

        Table 66: French 15-Year Perspective for Analgesics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
        Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-34

  4b. Germany                                                           III-35
      A.Market Analysis                                                 III-35
        Current and Future Analysis                                     III-35
        Competitive Scenario                                            III-35
         Table 67: Analgesics Market in Germany (2005): Market Share
         of Leading Players by Value - Bayer Group, Boehringer
         Ingelheim, Wyeth Consumer Healthcare, and Others (includes
         corresponding Graph/Chart)                                     III-35
      B.Market Analytics                                                III-36
        Table 68: German Recent Past, Current & Future Analysis for
        Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2001 through 2010 (includes
        corresponding Graph/Chart)                                      III-36

        Table 69: German Long-term Projections for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-37

        Table 70: German Historic Review for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 1991 through 2000 (includes corresponding
        Graph/Chart)                                                    III-37

        Table 71: German 15-Year Perspective for Analgesics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
        Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-38

  4c. The United Kingdom                                                III-39
      A.Market Analysis                                                 III-39
        Current and Future Analysis                                     III-39
        Key Player                                                      III-39
         Reckitt Benckiser Group Plc                                    III-39
        Competitive Scenario                                            III-39
         Table 72: Analgesics Market in the United Kingdom (2005E):
         Market Shares of Leading Players by Value - Boots
         Healthcare, GlaxoSmithKline, and Others (includes
         corresponding Graph/Chart)                                     III-39
         Ten Leading Analgesics Brands for Children in the UK
          Analgesics Market                                             III-39
        Strategic Corporate Developments                                III-39
      B.Market Analytics                                                III-40
        Table 73: UK Recent Past, Current & Future Analysis for
        Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2001 through 2010 (includes
        corresponding Graph/Chart)                                      III-40

        Table 74: UK Long-term Projections for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 2011 through 2015(includes corresponding
        Graph/Chart)                                                    III-41

        Table 75: UK Historic Review for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 1991 through 2000 (includes corresponding
        Graph/Chart)                                                    III-41

        Table 76: UK 15-Year Perspective for Analgesics by Product
        Segment - Percentage Breakdown of Dollar Sales for Internal
        Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
        and External Analgesics Markets for 1998, 2008 & 2012
        (includes corresponding Graph/Chart)                            III-42

  4d. Italy                                                             III-43
      A.Market Analysis                                                 III-43
        Current and Future Analysis                                     III-43
        Competitive Scenario                                            III-43
         Table 77: Analgesics Market in Italy (2005): Market Share
         of Leading Players by Value - Bayer Group, Angelini,
         Novartis, Bristol-Myers Squibb, Boots Healthcare, and
         Others (includes corresponding Graph/Chart)                    III-43
      B.Market Analytics                                                III-44
        Table 78: Italian Recent Past, Current & Future Analysis for
        Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2001 through 2010 (includes
        corresponding Graph/Chart)                                      III-44

        Table 79: Italian Long-term Projections for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-45

        Table 80: Italian Historic Review for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 1991 through 2000 (includes corresponding
        Graph/Chart)                                                    III-45

        Table 81: Italian 15-Year Perspective for Analgesics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
        Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-46

  4e. Spain                                                             III-47
      A.Market Analysis                                                 III-47
        Current and Future Analysis                                     III-47
        Competitive Scenario                                            III-47
         Table 82: Analgesics Market in Spain (2005): Market Share
         of Leading Players by Value - Bayer Group, Boehringer
         Ingelheim, Bristol-Myers Squibb, Novartis, Boots
         Healthcare, and Others (includes corresponding Graph/Chart)    III-47
      B.Market Analytics                                                III-48
        Table 83: Spanish Recent Past, Current & Future Analysis for
        Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2001 through 2010 (includes
        corresponding Graph/Chart)                                      III-48

        Table 84: Spanish Long-term Projections for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 2011 through 2015(includes
        corresponding Graph/Chart)                                      III-49

        Table 85: Spanish Historic Review for Analgesics by Product
        Segment - Internal Analgesics (Aspirin, Acetaminophen,
        Ibuprofen and Others) and External Analgesics Markets
        Independently Analyzed with Annual Sales Figures in US$
        Million for Years 1991 through 2000 (includes corresponding
        Graph/Chart)                                                    III-49

        Table 86: Spanish 15-Year Perspective for Analgesics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
        Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-50

  4f. Rest of Europe                                                    III-51
      A.Market Analysis                                                 III-51
        Current and Future Analysis                                     III-51
        Product Innovations/Introductions                               III-51
        Strategic Corporate Developments                                III-51
        Key Player                                                      III-52
         Novartis International AG (Switzerland)                        III-52
      B.Market Analytics                                                III-53
        Table 87: Rest of Europe Recent Past, Current & Future
        Analysis for Analgesics by Product Segment - Internal
        Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
        and External Analgesics Markets Independently Analyzed with
        Annual Sales Figures in US$ Million for Years 2001 through
        2010 (includes corresponding Graph/Chart)                       III-53

        Table 88: Rest of Europe Long-term Projections for
        Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-54

        Table 89: Rest of Europe Historic Review for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 1991 through 2000 (includes
        corresponding Graph/Chart)                                      III-54

        Table 90: Rest of Europe 15-Year Perspective for Analgesics
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen
        and Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-55

  5. Asia-Pacific                                                       III-56
      A.Market Analysis                                                 III-56
        Current and Future Analysis                                     III-56
        The OTC Analgesic Market                                        III-56
         OTC Analgesics Market in Asia-Pacific (2004): A Comparative
          Analysis of the Major Regions - Australia, China and South
           Korea                                                        III-56
        Aspirin - The Chinese Market                                    III-56
        Strategic Corporate Developments                                III-57
      B.Market Analytics                                                III-58
        Table 91: Asia-Pacific Recent Past, Current & Future
        Analysis for Analgesics by Product Segment - Internal
        Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
        and External Analgesics Markets Independently Analyzed with
        Annual Sales Figures in US$ Million for Years 2001 through
        2010 (includes corresponding Graph/Chart)                       III-58

        Table 92: Asia-Pacific Long-term Projections for Analgesics
        by Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-59

        Table 93: Asia-Pacific Historic Review for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 1991 through 2000 (includes
        corresponding Graph/Chart)                                      III-59

        Table 94: Asia-Pacific 15-Year Perspective for Analgesics by
        Product Segment - Percentage Breakdown of Dollar Sales for
        Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen and
        Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-60

  6. Latin America                                                      III-61
      A.Market Analysis                                                 III-61
        Current and Future Analysis                                     III-61
      B.Market Analytics                                                III-61
        Table 95: Latin American Recent Past, Current & Future
        Analysis for Analgesics by Product Segment - Internal
        Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
        and External Analgesics Markets Independently Analyzed with
        Annual Sales Figures in US$ Million for Years 2001 through
        2010 (includes corresponding Graph/Chart)                       III-61

        Table 96: Latin American Long-term Projections for
        Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-62

        Table 97: Latin American Historic Review for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 1991 through 2000 (includes
        corresponding Graph/Chart)                                      III-62

        Table 98: Latin American 15-Year Perspective for Analgesics
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen
        and Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-63

  7. Rest of World                                                      III-64
      A.Market Analysis                                                 III-64
        Current and Future Analysis                                     III-64
        Strategic Corporate Developments                                III-64
      B.Market Analytics                                                III-64
        Table 99: Rest of World Recent Past, Current & Future
        Analysis for Analgesics by Product Segment - Internal
        Analgesics (Aspirin, Acetaminophen, Ibuprofen and Others)
        and External Analgesics Markets Independently Analyzed with
        Annual Sales Figures in US$ Million for Years 2001 through
        2010 (includes corresponding Graph/Chart)                       III-64

        Table 100: Rest of World Long-term Projections for
        Analgesics by Product Segment - Internal Analgesics
        (Aspirin, Acetaminophen, Ibuprofen and Others) and External
        Analgesics Markets Independently Analyzed with Annual Sales
        Figures in US$ Million for Years 2011 through 2015 (includes
        corresponding Graph/Chart)                                      III-65

        Table 101: Rest of World Historic Review for Analgesics by
        Product Segment - Internal Analgesics (Aspirin,
        Acetaminophen, Ibuprofen and Others) and External Analgesics
        Markets Independently Analyzed with Annual Sales Figures in
        US$ Million for Years 1991 through 2000 (includes
        corresponding Graph/Chart)                                      III-65

        Table 102: Rest of World 15-Year Perspective for Analgesics
        by Product Segment - Percentage Breakdown of Dollar Sales
        for Internal Analgesics (Aspirin, Acetaminophen, Ibuprofen
        and Others) and External Analgesics Markets for 1998, 2008 &
        2012 (includes corresponding Graph/Chart)                       III-66


III-B. APPENDIX - POPULAR ANALGESIC BRANDS BY REGION

       Canada                                                           III-67
       France                                                           III-67
       Germany                                                          III-68
       United Kingdom                                                   III-69
        Leading Analgesics Brands for Children                          III-70
       Italy                                                            III-70
       Spain                                                            III-70
       Rest of Europe                                                   III-71
       Asia-Pacific                                                     III-77
       Latin America                                                    III-81


 IV. COMPETITIVE LANDSCAPE